UCB Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jean-Christophe Tellier

İcra Kurulu Başkanı

€12.4m

Toplam tazminat

CEO maaş yüzdesi	11.26%
CEO görev süresi	11.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	8.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jean-Christophe Tellier'un ücretlendirmesi UCB'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2025	€12m	€1m	€2b
Sep 30 2025	n/a	n/a	€1b
Jun 30 2025	n/a	n/a	€1b
Mar 31 2025	n/a	n/a	€1b
Dec 31 2024	€7m	€1m	€1b
Sep 30 2024	n/a	n/a	€653m
Jun 30 2024	n/a	n/a	€240m
Mar 31 2024	n/a	n/a	€292m
Dec 31 2023	€7m	€1m	€343m
Jun 30 2023	n/a	n/a	€332m
Mar 31 2023	n/a	n/a	€376m
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m

Tazminat ve Piyasa: Jean-Christophe 'nin toplam tazminatı ($USD 14.45M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.57M ).

Tazminat ve Kazançlar: Jean-Christophe 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Jean-Christophe Tellier (66 yo)

11.3yrs

Görev süresi

€12,434,367

Tazminat

Dr. Jean-Christophe Tellier is Chief Executive Officer of UCB Ventures S.A. Dr. Jean-Christophe Tellier is CEO & Executive Director of UCB SA from July 01, 2020. Dr. Tellier served as Executive Vice Presid...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Christophe Tellier	CEO & Executive Director	11.3yrs	€12.43m	Veri yok
Sandrine Dufour	Executive VP & CFO	5.8yrs	Veri yok	Veri yok
Alistair Henry	Executive VP & Chief Scientific Officer	2yrs	Veri yok	Veri yok
Denelle J. Johnson	Executive VP & General Counsel	3.1yrs	Veri yok	Veri yok
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	6.3yrs	Veri yok	Veri yok
Emmanuel Caeymaex	Executive Vice President of Patient Evidence	11.3yrs	Veri yok	Veri yok
Kirsten Lund-Jurgensen	Executive Vice President of Patient Supply	2.3yrs	Veri yok	Veri yok
Fiona du Monceau	Executive VP of Patient Impact & Chief Commercial Officer	2.1yrs	Veri yok	Veri yok
Caroline Vancoillie	Chief Accounting Officer & Head of Group Finance	13.2yrs	Veri yok	Veri yok
Gwendoline Ornigg	Head of Global Corporate Communication	no data	Veri yok	Veri yok
Veronique Toully	Head of Sustainability	no data	Veri yok	Veri yok
Martin Citron	VP & Head of Neuroscience TA New Medicines	no data	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim: UNC 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jean-Christophe Tellier	CEO & Executive Director	12.1yrs	€12.43m	Veri yok
Gerhard Mayr	Honorary Chairman	no data	€70.00k	Veri yok
Mark Eyskens	Honorary Chairman	21.3yrs	€15.50k	Veri yok
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	Veri yok
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	Veri yok
Diégo du de Bergendal	Honorary Chairman	5.1yrs	€87.50k	Veri yok
Karel Boone	Honorary Chairman	no data	€49.00k	Veri yok
Judy L. Brown	Independent Director	less than a year	Veri yok	Veri yok
Jonathan Peacock	Independent Chair of the Board	5.1yrs	€438.33k	Veri yok
Charles-Antoine Janssen	Vice-Chair of the Board	14.1yrs	€192.33k	Veri yok
Nefertiti Greene	Independent Director	2.3yrs	€197.33k	Veri yok
Jonkheer van Rijckevorsel	Director	12.1yrs	€157.83k	Veri yok

8.6yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: UNC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/21 09:08
Gün Sonu Hisse Fiyatı	2026/05/21 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

UCB SA 40 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Charles Pitman	Barclays
Brian Bourdot	Barclays
Charles Pitman	Barclays

UCB Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

UCB SA Announces Step Down of Fiona Du Monceau from the Board of Directors

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

Recent updates

Ucb Announces Superior Efficacy of Bimzelx over Skyrizi in Psoriatic Arthritis

UCB SA (ENXTBR:UCB) signed a definitive agreement to acquire Candid Therapeutics, Inc. from Vida Ventures Advisors, LLC and Two River Group Holdings, LLC for $2.2 billion.

UCB SA (ENXTBR:UCB) signed a definitive agreement to acquire Neurona Therapeutics, Inc. for approximately $1.2 billion.

UCB Presents New Data Demonstrating Quality-of-Life Impacts for Epilepsy Patients and Caregivers at AAN 2026 Meeting

UCB SA Presents New Clinical Data from Its Generalized Myasthenia Gravis Portfolio At the American Academy of Neurology Meeting

UCB Announces New BIMZELX (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

UCB Announces Bimzelx Demonstrates Superiority Over Skyrizi In Active Psoriatic Arthritis

UCB Presents Positive Results from GEMZ Phase 3 Study at AES Showing Fenfluramine Significantly Reduced Countable Motor Seizures in CDKL5 Deficiency Disorder

UCB to Present 21 Abstracts at American Epilepsy Society Annual Meeting

U.S. FDA Approves KYGEVVI®? (doxecitine and doxribtimine), the First and Only Treatment for Adults and Children Living with Thymidine Kinase 2 Deficiency (TK2d)

UCB Announces Three-Year Data from the BE HEARD Trials for BIMZELX®

UCB SA to Unveil New Data for RYSTIGGO (rozanolixizumab-noli) and ZILBRYSQ for gMG

UCB Announces New Three-Year Data from Phase 3 Trials, and Their Open-Label Extensions

UCB Announces Results from Multicenter Retrospective Chart Review Study of Investigational Pyrimidine Nucleoside and/or nucleotide Therapy in Patients with Thymidine Kinase 2 Deficiency

UCB Announces Three- and Four-Year Data from Across the Open-Label Extension Phase 3 Trials for BIMZELX®? in Moderate-To-Severe Plaque Psoriasis

UCB Announces Three-Year Data from the BE HEARD Trials for BIMZELX

UCB Announces Results from the Rheum for Improvement Survey

UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency Disorder

UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus

UCB SA to Report First Half, 2025 Results on Jul 31, 2025

UCB Presents Latest Research Across Leading Neurology Portfolio At American Academy of Neurology (AAN) Meeting

UCB SA Announces Step Down of Fiona Du Monceau from the Board of Directors

UCB Announces Positive Data from Studies Inviding Its Investigational Therapy, Doxecitine and Doxribtimine

Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of Fintepla (Fenfluramine) in Children and Adults with Dravet Syndrome

UCB SA Proposes Dividend

UCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis Market

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Full year 2023 earnings released: EPS: €1.81 (vs €2.22 in FY 2022)

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021)

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

First half 2022 earnings released

UCB SA, Annual General Meeting, Apr 27, 2023

Upcoming dividend of €0.91 per share

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

Director has left the company

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Revenue beats expectations

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

New 90-day low: €84.00

New 90-day low: €89.16

New 90-day low: €95.06

CEO Tazminat Analizi

CEO